Consonance Capital Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-2,998
| Closed | -$706K | – | 7 |
|
|
2022
Q2 | $706K | Sell |
2,998
-21,565
| -88% | -$4.38M | 2.98% | 4 |
|
|
2022
Q1 | $4.41M | Sell |
24,563
-35,275
| -59% | -$6.72M | 7.48% | 6 |
|
|
2021
Q4 | $12.9M | Sell |
59,838
-98,000
| -62% | -$19.2M | 8.43% | 5 |
|
|
2021
Q3 | $29.1M | Sell |
157,838
-1,249
| -0.8% | -$246K | 15.95% | 3 |
|
|
2021
Q2 | $28.5M | Sell |
159,087
-399,075
| -71% | -$76M | 3.44% | 9 |
|
|
2021
Q1 | $93.4M | Buy |
558,162
+29,198
| +6% | +$4.87M | 9.95% | 1 |
|
|
2020
Q4 | $80.3M | Buy |
+528,964
| New | +$69.4M | 7.5% | 1 |
|
|
2020
Q2 | – | Sell |
-1,350,360
| Closed | -$128M | – | 37 |
|
|
2020
Q1 | $128M | Buy |
1,350,360
+431,097
| +47% | +$41M | 9.53% | 2 |
|
|
2019
Q4 | $81M | Sell |
919,263
-48,306
| -5% | -$4.25M | 4.94% | 5 |
|
|
2019
Q3 | $77.2M | Buy |
967,569
+196,800
| +26% | +$15.8M | 7.64% | 3 |
|
|
2019
Q2 | $60.2M | Sell |
770,769
-454,618
| -37% | -$42.5M | 4.26% | 7 |
|
|
2019
Q1 | $144M | Buy |
1,225,387
+124,790
| +11% | +$14.5M | 9.08% | 2 |
|
|
2018
Q4 | $120M | Buy |
1,100,597
+238,302
| +28% | +$27.6M | 8.81% | 5 |
|
|
2018
Q3 | $110M | Buy |
862,295
+295,369
| +52% | +$36.5M | 5.94% | 3 |
|
|
2018
Q2 | $64.1M | Hold |
566,926
| – | – | 4.14% | 11 |
|
|
2018
Q1 | $63.7M | Buy |
+566,926
| New | +$72M | 5.82% | 6 |
|
|
2017
Q2 | – | Sell |
-642,168
| Closed | -$86.9M | – | 23 |
|
|
2017
Q1 | $86.9M | Buy |
642,168
+61,467
| +11% | +$9.31M | 9.11% | 2 |
|
|
2016
Q4 | $83.3M | Sell |
580,701
-237,999
| -29% | -$30.4M | 9.15% | 3 |
|
|
2016
Q3 | $96.7M | Buy |
818,700
+400,000
| +96% | +$48.1M | 9.31% | 4 |
|
|
2016
Q2 | $44.3M | Buy |
+418,700
| New | +$46.7M | 6.28% | 9 |
|
|
2015
Q3 | – | Sell |
-387,186
| Closed | -$67.4M | – | 32 |
|
|
2015
Q2 | $67.4M | Sell |
387,186
-325,000
| -46% | -$58.5M | 6.77% | 6 |
|
|
2015
Q1 | $123M | Buy |
712,186
+52,000
| +8% | +$7.93M | 11.18% | 1 |
|
|
2014
Q4 | $85.5M | Sell |
660,186
-101,576
| -13% | -$13.1M | 11.01% | 2 |
|
|
2014
Q3 | $98M | Buy |
761,762
+334,972
| +78% | +$34.5M | 13.45% | 1 |
|
|
2014
Q2 | $37.8M | Sell |
426,790
-242,900
| -36% | -$23.4M | 5.62% | 5 |
|
|
2014
Q1 | $63M | Buy |
669,690
+91,000
| +16% | +$9.31M | 9.37% | 1 |
|
|
2013
Q4 | $65.4M | Buy |
578,690
+110,500
| +24% | +$9.96M | 10.73% | 1 |
|
|
2013
Q3 | $36.9M | Buy |
468,190
+60,024
| +15% | +$4.39M | 9.23% | 2 |
|
|
2013
Q2 | $26.9M | Buy |
+408,166
| New | +$26.3M | 9.55% | 3 |
|
Other funds holding UTHR
ACA
APM
PAI
Consonance Capital Management's UTHR Position: Q3 2022 in Review
Consonance Capital Management sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 2,998 shares — an estimated $706K sold.
Consonance Capital Management first reported a position in UTHR in Q2 2013 and held it in 29 quarters. The position peaked at $144M in Q1 2019. 461 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.
- Consonance Capital Management reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
- Consonance Capital Management sold 2,998 United Therapeutics shares in Q3 2022, an estimated $706K.
- Consonance Capital Management first reported a position in United Therapeutics in Q2 2013 and held it in 29 quarters.
- Consonance Capital Management's United Therapeutics position peaked at $144M in Q1 2019.
- 461 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.
Based on Consonance Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.